Genes help explain GLP‑1 results
A big genetics study found common variants in two genes that partly predict who loses the most weight on GLP‑1 drugs — and who’s likelier to get nausea or vomiting as a side effect. (nature.com) The analysis covered almost 28,000 people and the result is practical: genetics won’t explain everything, but it’s now a measurable factor when doctors and patients consider GLP‑1 therapy. (nature.com) Reporters and data partners (including 23andMe) are already using those variants to begin predicting response patterns in clinic‑scale samples. (statnews.com)
These drugs copy a gut hormone that tells your brain you’ve eaten enough, so many people feel full sooner and eat less after a weekly shot of semaglutide or tirzepatide. Semaglutide is sold as Wegovy and Ozempic, and tirzepatide is sold as Zepbound and Mounjaro. (nature.com) The puzzle is that two people can take the same medicine for months and get very different results. One person may lose a large share of body weight, while another loses little and spends the first weeks dealing with nausea or vomiting. (nature.com) A gene is an instruction sheet for making a protein, and a variant is a one-letter spelling change in that sheet. The new study asked whether common spelling changes in the genes touched by these drugs can nudge results up or down. (nature.com) The researchers used a genome-wide association study, which is a giant comparison of DNA across many people to see which variants travel with a trait. They analyzed self-reported outcomes from 27,885 people who had used a glucagon-like peptide-1 drug for weight loss. (nature.com) One hit showed up in a gene called glucagon-like peptide-1 receptor, which makes the receptor that semaglutide is designed to press like a doorbell. People carrying the effect version lost about 0.76 kilograms more per copy of that variant than non-carriers. (nature.com) A second signal showed up in a gene called glucose-dependent insulinotropic polypeptide receptor, which helps explain why tirzepatide can behave differently from semaglutide. Variants in that gene were linked to nausea and vomiting, but that link appeared only in people using tirzepatide. (nature.com) The side-effect story did not come from one gene alone. The study also found links between nausea or vomiting and variation in the glucagon-like peptide-1 receptor gene itself, which means the same biological pathway tied to weight loss also seems tied to tolerability. (nature.com) This does not mean a DNA test can tell you exactly what will happen after your first injection. Nature’s news write-up says genetics explained only part of the spread in outcomes, alongside age, sex, starting body mass index, dose, and other clinical factors. (nature.com) It is still practical because “partly predictable” is better than “total guesswork” when a drug can cost hundreds of dollars a month and make some patients stop early. The authors built a model that combined genetic, demographic, and clinical data and showed it could sort patients by both expected weight loss and side-effect risk. (nature.com) That is already moving from paper to product. STAT reported on April 8, 2026 that 23andMe is using the two variants in a clinic-scale report for members of its Total Health service to estimate patterns of weight loss response and nausea risk before treatment decisions are made. (statnews.com) The near-term use is not “pick the perfect drug from DNA alone.” The near-term use is more modest: warn a patient that tirzepatide may carry a higher nausea risk for their profile, or tell a slow responder that biology may be part of the reason and dose changes or a different drug may be worth discussing. (nature.com)
